Natera (NTRA) Stock Buy Rating Kept at Canaccord Genuity; The Target Price Given is $20; BRAMBLES LTD ORDINARY SHARES AUSTRALIA (BMBLF) Sellers Decreased By 39.07% Their Shorts

Brambles Limited (OTCMKTS:BMBLF) Logo

In analysts report released on 25 June, Natera (NASDAQ:NTRA) stock Buy was reaffirmed by Canaccord Genuity. They currently have a $20 price target on the stock. Canaccord Genuity’s price target would suggest a potential upside of 24.46% from the company’s last stock close.

BRAMBLES LTD ORDINARY SHARES AUSTRALIA (OTCMKTS:BMBLF) had a decrease of 39.07% in short interest. BMBLF’s SI was 603,800 shares in June as released by FINRA. Its down 39.07% from 991,000 shares previously. It closed at $7 lastly. It is down 0.00% since June 25, 2017 and is . It has underperformed by 12.57% the S&P500.

The stock increased 14.46% or $2.03 during the last trading session, reaching $16.07. About 986,012 shares traded or 416.60% up from the average. Natera, Inc. (NASDAQ:NTRA) has risen 12.60% since June 25, 2017 and is uptrending. It has outperformed by 0.03% the S&P500. Some Historical NTRA News: 09/04/2018 – Natera Appoints Paul R. Billings, M.D., Ph.D., as Chief Medical Officer; 13/03/2018 – NATERA INC SEES 2018 COST OF REVENUES TO BE APPROXIMATELY 60% TO 65% OF REVENUES; 10/05/2018 – Franklin Advisers Inc. Exits Position in Natera; 09/05/2018 – NATERA INC NTRA.O : MORGAN STANLEY RAISES TARGET PRICE TO $16 FROM $15; 08/05/2018 – NATERA INC NTRA.O : COWEN AND COMPANY RAISES TARGET PRICE TO $14 FROM $12; 13/03/2018 – Natera 4Q Loss $45.5M; 08/05/2018 – Natera 1Q Rev $62.3M; 08/05/2018 – NATERA INC NTRA.O FY2018 REV VIEW $254.7 MLN — THOMSON REUTERS l/B/E/S; 10/04/2018 – Natera Closes Above 50-Day Moving Average: Technicals; 05/03/2018 Natera’s Genetic Tests Now Fully Integrated into Yale New Haven Health’s Epic EMR System

Among 8 analysts covering Natera Inc (NASDAQ:NTRA), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Natera Inc has $25 highest and $12.0 lowest target. $16.38’s average target is 1.93% above currents $16.07 stock price. Natera Inc had 27 analyst reports since July 27, 2015 according to SRatingsIntel. As per Friday, August 14, the company rating was upgraded by Morgan Stanley. The stock of Natera, Inc. (NASDAQ:NTRA) earned “Buy” rating by Robert W. Baird on Wednesday, March 14. Wedbush maintained Natera, Inc. (NASDAQ:NTRA) on Friday, August 28 with “Neutral” rating. The company was maintained on Wednesday, March 14 by Canaccord Genuity. Morgan Stanley maintained Natera, Inc. (NASDAQ:NTRA) on Wednesday, May 9 with “Overweight” rating. Morgan Stanley maintained Natera, Inc. (NASDAQ:NTRA) rating on Friday, October 6. Morgan Stanley has “Overweight” rating and $16 target. The stock of Natera, Inc. (NASDAQ:NTRA) earned “Buy” rating by Canaccord Genuity on Monday, October 23. The rating was maintained by Cowen & Co with “Buy” on Wednesday, July 19. The stock has “Equal Weight” rating by Morgan Stanley on Monday, July 27. On Tuesday, April 19 the stock rating was initiated by Benchmark with “Buy”.

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. The company has market cap of $876.02 million. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrierÂ’s children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. It currently has negative earnings. The firm also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father.

More notable recent Natera, Inc. (NASDAQ:NTRA) news were published by: Seekingalpha.com which released: “Key events next week – healthcare” on June 21, 2018, also Streetinsider.com with their article: “Natera (NTRA) Announces Powerful Kidney Transplant Rejection Biomarker” published on June 21, 2018, Seekingalpha.com published: “Stocks To Watch: More Trade Tiffs And Stress Tests” on June 23, 2018. More interesting news about Natera, Inc. (NASDAQ:NTRA) were released by: Globenewswire.com and their article: “Analysis: Positioning to Benefit within Second Sight Medical Products, ICF International, Morningstar, Spark …” published on June 21, 2018 as well as Streetinsider.com‘s news article titled: “Natera (NTRA) Reports New Clinical Utility Data & Issuance of CPT Code for NIPT in Twin Pregnancies” with publication date: June 13, 2018.

Analysts await Natera, Inc. (NASDAQ:NTRA) to report earnings on August, 14. They expect $-0.53 EPS, down 1.92% or $0.01 from last year’s $-0.52 per share. After $-0.61 actual EPS reported by Natera, Inc. for the previous quarter, Wall Street now forecasts -13.11% EPS growth.

Natera, Inc. (NASDAQ:NTRA) Ratings Chart